Initial supplementary dose of dolutegravir in second-line antiretroviral therapy: a noncomparative, double-blind, randomized placebo-controlled trial

<p><strong>Background:</strong> Dolutegravir concentrations are reduced by efavirenz induction effect necessitating twice-daily dolutegravir dosing when coadministered. Efavirenz induction persists for several weeks after stopping, which could potentially select for dolutegravir re...

詳細記述

書誌詳細
主要な著者: Zhao, Y, Griesel, R, Omar, Z, Simmons, B, Hill, A, van Zyl, G, Keene, C, Maartens, G, Meintjes, G
フォーマット: Journal article
言語:English
出版事項: Oxford University Press 2023

類似資料